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Abstract
Purpose
Inhibiting VEGF is the gold standard treatment for neovascular age-related macular degen-
eration (AMD). It is also effective in preventing retinal oedema and neovascularisation (NV)
in diabetic retinopathy (DR) and retinal vein occlusions (RVO). Neuropilin 1 (Nrp1) is a co-
receptor for VEGF and many other growth factors, and therefore a possible alternative drug
target in intra ocular neovascular disease. Here we assessed choroidal and retinal NV in an
inducible, endothelial specific knock out model for Nrp1.
Methods
Crossing Nrp1 floxed mice with Pdgfb-CreERT2 mice produced tamoxifen-inducible, endo-
thelial specific Nrp1 knock out mice (Nrp1ΔEC) and Cre-negative, control littermates. Cre-
recombinase activity was confirmed in the Ai3(RCL-EYFP) reporter strain. Animals were
subjected to laser-induced CNV (532 nm) and spectral domain-optical coherence tomogra-
phy (SD-OCT) was performed immediately after laser and at day 7. Fluorescein angiogra-
phy (FA) evaluated leakage and postmortem lectin staining in flat mounted RPE/choroid
complexes was also used to measure CNV. Furthermore, retinal neovascularisation in the
oxygen induced retinopathy (OIR) model was assessed by immunohistochemistry in retinal
flatmounts.
Results
In vivo FA, OCT and post-mortem lectin staining showed a statistically significant reduction
in leakage (p<0.05), CNV volume (p<0.05) and CNV area (p<0.05) in the Nrp1ΔEC mice
compared to their Cre-negative littermates. Also the OIR model showed reduced retinal NV
in the mutant animals compared to wild types (p<0.001).
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Conclusion
We have demonstrated reduced choroidal and retinal NV in animals that lack endothelial
Nrp1, confirming a role of Nrp1 in those processes. Therefore, Nrp1 may be a promising
drug target for neovascular diseases in the eye.
Introduction
A final common complication for multiple retinal diseases, such as age related macular degen-
eration (AMD), diabetic retinopathy (DR) and retinal vein occlusions (RVO) is the growth of
abnormal neovascular blood vessels (neovascularisation) with increased permeability that pro-
duce fluid leakage in the macula [1,2], which can lead to vision loss. Neovascularization may
originate from choroidal blood vessels (CNV) invading Bruch’s membrane and the subretinal
space, or from the retinal vasculature. In both cases the abnormal angiogenesis is often driven
by excessive production of vascular endothelial growth factor (VEGF), and inhibiting VEGF is
the current gold standard in the treatment of neovascular AMD [3]. Moreover, intravitreal
administration of VEGF blockers (Ranibizumab, Aflibercept and off-label Bevacizumab) is
also effective in preventing retinal oedema and neovascularisation in DR and RVO [4,5]. How-
ever, there are limitations. Although VEGF blockage can halt pathological angiogenesis, reduce
vessel leakage and cause regression of existing vessels [6], it does not address the causes that
drive the disease and requires monthly/bimonthly intravitreal injections. Furthermore, they
are only beneficial in subsets of patients [7]. There is also the concern that VEGF is a neuronal
survival factor and sustained blocking of VEGF may have undesirable side effects [1,2]. It is
therefore important to explore alternative molecular targets for the development of therapies
blocking retinal angiogenesis.
Besides VEGF, there are several other factors known to regulate angiogenesis, such as trans-
forming growth factor beta (e.g. TGFB1), fibroblast growth factors (e.g. FGF2), semaphorins
(e.g. SEMA3E) and angiopoietins (e.g. ANGPT2) [8–12]. Neuropilin 1 (NRP1) functions as a
co-receptor for several of these ligands (e.g. VEGF, TGFB1, FGF2 and semaphorins) [13–16]
and might therefore be a promising target to interfere with multiple signalling pathways simul-
taneously to overcome VEGF-resistance. In this context it is noteworthy that genetic variation
in Nrp1 seems to influence treatment responses to anti-VEGF therapy in neovascular AMD
[17].
The general importance of NRP1 in angiogenesis has previously been demonstrated in
numerous studies. For instance, Nrp1 null mutations in mice cause serious vascular abnormal-
ities [18,19] and deficient endothelial tip cell function in sprouting angiogenesis [20,21] during
embryogenesis. Several studies on cultured endothelial cells showed an involvement of Nrp1
in VEGF—VEGFR2 signalling [22–24]. However, mice harbouring a non-VEGF binding
mutant form of Nrp1 develop normally [25], suggesting that the essential function of Nrp1 in
sprouting angiogenesis depends on ligands other than VEGF. In fact, two recent studies
showed that Nrp1 critically regulates TGFB/BMP signalling in central nervous system (CNS)
vascular development [26,27].
Since sprouting angiogenesis not only contributes to vessel growth during embryogenesis
but also to neovascularisation in adult eye pathologies, we assessed the role of Nrp1 in choroi-
dal and retinal neovascularisation in endothelium specific, inducible Nrp1 knockout
(Nrp1ΔEC) mice. CNV in mice was triggered by laser lesions, which is a widely accepted and
reproducible model that mimics many features of CNV occurring in the wet form of AMD.
Nrp1 and Neovascularisation
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Although the acute laser injury does not mimic the chronic disease condition in humans, the
model is useful for the investigation of the cellular and molecular mechanisms that drive CNV.
We also used the oxygen induced retinopathy (OIR) model [28,29] to study effects on neovas-
cularisation in the retinal vasculature.
Animals, Materials and Methods
Animals
All animals were handled in accordance with the United Kingdom (UK) Animals (Scientific
Procedures) Act 1986 and all experiments were covered by a project license approved by the
UK Home Office (PPL7157) and the University College of London (UCL) Institute of Oph-
thalmology (IOO) Ethics Sub-Committee. Due to lethality of Nrp1 knock out animals it was
necessary to use an inducible Cre-lox approach. We therefore crossed a tamoxifen-inducible,
endothelial cell specific Cre strain (Pdgfb-CreER mice) [30] with Nrp1 floxed [18] mice, creat-
ing endothelial specific Nrp1 knock out mice (Nrp1ΔEC). Cre negative littermates were used as
controls. Cre recombinase was induced in adult animals (6–8 weeks old) by injecting 200 μl of
tamoxifen (15 mg/ml in soybean oil; Sigma-Aldrich) i.p. daily for 4 days before laser applica-
tion. To assess Cre recombinase activity the reporter strain Ai3(RCL-EYFP) was used (condi-
tionally expressing EYFP from a CAG promoter in the ROSA locus).
Laser CNV model
Mice were anesthetized with a mixture (i.p.) of Ketamine (Ketaset, Lyon, France, 75 mg/kg)
and xylazine (Domitor 2%, 10mg/kg; Bayer Animal Health, Leverkusen, Germany). Pupils
were dilated with a mixture of tropicamide 0.5% (Bausch and Lomb) and phenylephrine 1%
(Bausch and Lomb) and a diode laser (wavelength 532 nm, Micron III, Phoenix Research,
USA) with a power of 120 mW, an exposure time of 0.1 seconds and a spot size of 50 μm was
used to induce 3–4 CNV lesions in the retina. Laser lesions were applied approximately two
optic discs from the optic nerve, while avoiding major blood vessels. Vaporisation bubble for-
mation confirmed the rupture of Bruch’s Membrane [31] and those spots that did not result in
the formation of a bubble were excluded. Laser photocoagulation sites that developed CNV
were analysed 1 week after laser application.
OIR model
Litters were placed in 75% oxygen chamber fitted with an oxygen controller (PROOX 110;
Reming Bioinstruments Co., Redfield, USA) from P7-12 and kept a room air until P17 [28].
Cre recombinase was activated by i.p. injection of 4-hydroxy-tamoxifen (OHT) at P11 (in the
OIR model, 5μg/pup) or at P3 (2μg/pup to test Nrp1 deletion efficiency). Eyes were then pro-
cessed for wholemount immunohistochemistry as previously described [30], using antibodies
against Nrp1 (1:200, R&D systems, AF566), collagen IV (1:200, AbD Serotec, 2150–1470), con-
jugated α-smooth muscle actin (ASMA, 1:200, Cy3-conjugated, Sigma Aldrich, C6198) and
FITC-conjugated isolectin B4 (1:200, Vector Labs). Wholemounts of retinas were imaged and
analysed according to published protocols [32]. This involved manually tracing and quantify-
ing the neovascular and avascular areas with ImageJ.
In vivo imaging
OCT horizontal scans (400x400x1024 voxels), centred on the optic nerve head, were obtained
from both eyes of the mice using an R2200 UHR SD-OCT scanner (Bioptigen Inc., Morrisville,
NC, USA) on day 0 (0.5–1 hour after laser application) to confirm rupture of Bruch’s
Nrp1 and Neovascularisation
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membrane and on day 7 to measure the volume of CNV lesions. Images were captured by In
Vivo Vue software (Bioptigen Inc.) and the obtained scans were converted to avi-files in order
to measure the volume with Fiji Software V1.48q (a distribution of ImageJ). Measurements
were made by two independent investigators.
A scanning laser ophthalmoscope (Spectralis™ HRA, Heidelberg Engineering, Heidel-
berg, Germany) with a 55˚ field of view lens was used to assess EYFP expression in Cre
reporter mice. One week after laser application, animals were subjected to fluorescein
angiographic evaluation. Fluorescein angiograms were obtained using a retinal imaging
microscope (Micron III, Phoenix Research, USA) was used. Briefly, after pupil dilation
anaesthetised animals were i.p. injected with 100 μl of 10% sodium fluorescein and images
were obtained after 1–2 min (early leakage) and 6–7 min (late leakage). Area of leakage was
measured by two trained independent investigators using Fiji Software V1.48q (a distribu-
tion of ImageJ).
Post-mortem histology
After sacrificing the animals, eyes were enucleated and immediately fixed in 4% paraformalde-
hyde for 10–15 minutes. Retinas and scleras (with choroid and RPE attached) were dissected
separately and flattened by making radial cuts. In order to assess recombination efficiency in
the reporter strain, YFP fluorescence was imaged by confocal microscope (LSM710, Carl Zeiss,
Meditec, Dublin, CA) directly in wholemounts of RPE-choroid complexes and in cryosections.
Whole mounts and cryosections were also subjected to immunohistochemistry to visualise
vessels and inflammatory cells using biotinylated isolectin (1:200, IB4, Vector Labs), CD11b
(1:200, Abcam, ab64347), Nrp1 (1:200, R&D systems, AF566), Hoechst 33258 (1:1000, Sigma-
Aldrich), streptavidin coupled to Alexa Fluor1 594 (1:250, Life Technologies) and chicken
anti-rat IgG Alexa Fluor1 647 conjugated (1:200, Life Technologies). CNV lesion areas were
captured by confocal microscopy and measured by two independent and trained investigators
by using Fiji Software V1.48q (a distribution of ImageJ).
Statistical analysis
Only laser lesions that developed CNV were included in the statistical analysis. Exclusion crite-
ria were the absence of a visible vaporisation bubble at the time of laser application, no evi-
dence of BM rupture (as observed by OCT immediately after laser application) and the
presence of haemorrhage (larger than the laser spot). A non-parametric Kruskal-Wallis test
was performed to assess differences between control and Nrp1ΔEC animals, using SPSS statis-
tics software (SPSS Inc., Chicago, IL). N-numbers refer to the number of mice throughout the
manuscript.
Results
Confirmation of Cre recombinase activity
In order to confirm that the Pdgfb-CreER strain can drive Cre recombination in the adult cho-
roidal vasculature, the Ai3(RCL-EYFP) reporter strain was used. One week after laser injury,
in vivo laser scanning ophthalmoscopy revealed pronounced fluorescence in most vessels and
in laser lesions in animals with the Cre allele but not in Cre negative controls (Fig 1A and 1B).
Enhanced yellow fluorescent protein (EYFP) fluorescence was confirmed by confocal micros-
copy on post-mortem choroid whole mount preparations (Fig 1C and 1D) and on cryosections
through laser lesions (Fig 1E and 1F). This demonstrated that the Pdgfb-CreER strain effec-
tively causes recombination of floxed alleles in the adult choroidal vasculature. No differences
Nrp1 and Neovascularisation
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in vessel growth or health were observed between CreER positive or negative animals (neither
during development nor in the adult) in the absence of tamoxifen induction, suggesting the
CreER transgene did not have any off-target effects.
The Pdgfb-CreER strain was crossed with a Nrp1-floxed strain to produce offspring with or
without the CreER transgene in a homozygous Nrp1-floxed background. Upon tamoxifen
treatment, Nrp1 protein was depleted in choroidal endothelial cells (arrows in Fig 1) in CreER
positive (Nrp1ΔEC) but not in CreER negative (Wt) animals (Fig 1G–1J). CD11b positive
microglial cells (arrowheads in Fig 1) maintained Nrp1 expression, irrespective of genotype
(Fig 1K–1N), confirming the endothelial specificity of the Nrp1 depletion.
Fig 1. Confirmation of Cre recombinase activity and Nrp1 deletion in the choroidal vasculature. A YFP reporter strain (A-F) was used
to demonstrate recombination activity in animals carrying the tamoxifen-inducible transgene Pdgfb-CreER (B, D, F). CreER negative animals
were used as a negative control (A, C, E). In vivo imaging (A, B) using the fluorescein channel in a Spectralis ophthalmoscope focused on the
choroid showed YFP expression in most vessels, including laser-induced neovascular foci. Microscopy on postmortem tissue also
demonstrates pronounced YFP fluorescence in laser-induced CNV lesions in choroidal flatmounts (C, D), and in cross sections (E, F)
showing Hoechst staining (blue) and YFP fluorescence (green). Microscopy on cross sections from the choroid from Nrp1ΔEC mice (H, J, M,
N) or wild type controls (G, I, K, L) was used to demonstrate deletion of Nrp1 from endothelial cells (white arrows) by immunohistochemistry
against Nrp1 (green in G, H, white in I, J). Nrp1 expressed by microglia (arrowheads), stained with anti-CD11b (red in G, H, white in K, M),
was not targeted (I, J). Asterisks in G, H indicate autofluorescent RPR. Scale bars in D, F are 100 μm and in J 10 μm.
doi:10.1371/journal.pone.0169865.g001
Nrp1 and Neovascularisation
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CNV in vivo volume is reduced in Nrp1ΔEC animals
To assess the effects of vascular Nrp1 depletion on neovascularisation in the retina, we utilised
the laser-induced CNV model. OCT was used to measure CNV lesions in vivo. Firstly, rupture
of Bruch’s membrane was confirmed immediately after the laser lesions were applied (Fig 2A
and 2B). Then, 7 days later the laser lesions were re-examined using volume scans (Fig 2C and
2D). The volumes of CNVs within the lesions were measured by assessing the area of the
CNVs (red stippled outline in Fig 2E and 2F) in each b-scan (Fig 2G). This showed a statisti-
cally significant (p = 0.018) reduction in CNV volume in transgenic animals compared to wild
type mice (Fig 2H).
Reduced leakage and CNV areas in Nrp1ΔEC animals
The effects of endothelial Nrp1 deletion on CNV growth were also evaluated by fluorescein
angiography (FA, Fig 3A and 3B) and post-mortem histology (Fig 3D and 3E). Measuring the
hyper fluorescent areas in FA images showed a reduction in the Nrp1ΔEC animals (p = 0.026,
Fig 3C). Similarly, CNV areas measured in post-mortem histology (using IB4 lectin staining),
also revealed a statistically significant (p = 0.026) reduction in lesion size in Nrp1ΔEC mice ver-
sus Cre negative control mice (Fig 3F), confirming the OCT volume measurements by two
independent assessment methods.
Reduced neovascularisation in the OIR model in Nrp1ΔEC mice
In order to gain further insight about the role of Nrp1 in vascular pathologies in the retina, we
also assessed the developing retinal vasculature. First, CreER efficiency was demonstrated in
the retinal vasculature in Nrp1ΔEC mice at the perinatal stage, by immunohistochemistry
against Nrp1 on retinal wholemounts from postnatal day (P)5 pups that have been injected
with OHT at P3 (Fig 4A–4D). This clearly confirmed endothelial cell specific Nrp1 depletion,
whereas Nrp1 in microglial cells ahead of the developing plexus (arrowheads in Fig 4) was not
affected. Furthermore, the growing edge of the developing retinal vasculature displayed less
and thicker sprouting tips in Nrp1ΔEC mice (Fig 1A–1C) as previously described [26].
We also assessed neovascular growth in the OIR model [28,29]. In this model perinatal
mice are exposed to high oxygen levels, which depletes capillaries in the developing retinal vas-
culature, resulting in abnormal neovascular tuft formation upon return to room air. OHT was
injected at P11 and neovascularisation was quantified at P17, which was significantly reduced
in Nrp1ΔEC animals compared to wild type litter mates (Fig 4E–4I). Interestingly, the remain-
ing avascular area was larger in the mutant animals (Fig 4E–4H and 4J), suggesting that nor-
mal, regenerative vascular growth was also affected by Nrp1 deletion.
Discussion
In this study we have demonstrated that Nrp1 mediated signalling is involved in neovasculari-
sation during CNV development as well as during OIR, and could be a drug target in ocular
neovascular diseases. CNV volume and fluorescein leakage were both reduced in the laser-
induced CNV model in the absence of endothelial Nrp1, but the precise molecular mechanism
of this effect is not understood yet. On the one hand VEGF is a well-established ligand for
Nrp1 and is known to drive angiogenesis and vascular permeability during intraocular vascu-
lar disease [33,34]. On the other hand, Nrp1 is involved in aspects of TGFB superfamily signal-
ling during sprouting angiogenesis [26,27]. More specifically, Nrp1 has been shown to be
essential in endothelial tip-cells in developing brain blood vessels [20]. This may be based on
its role in supressing the stalk-cell phenotype in endothelial tip-cells via the modulation of
Nrp1 and Neovascularisation
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Fig 2. Laser-induced CNV assessed by OCT. In vivo OCT images obtained immediately after laser burns
were applied, demonstrate Bruch’s membrane ruptures (asterisks in A, B) in WT (left column) and Nrp1ΔEC
(right column) mice. One week after laser-induction, CNV lesions were imaged and quantified (C-H). The top
panels in C, D represent 3D reconstructions of the RPE and CNV lesion surfaces. The bottom panels in C, D
are cross sections along the black lines in the panels above (red corresponds to white the black and white
images and indicates the RPE. Dotted red lines in E, F indicate the lesion borders measured, which were
reconstructed into 3D volumes (G) with a distance of 14 μm between each frame. CNV volume measurement
box-plots show significant volume reduction in Nrp1ΔEC compared to WT mice (P<0.05; n = 7). RGC: Retinal
Ganglion Cell; IPL: Inner Plexiform Layer; INL: Inner Nuclear Layer; OPL: Outer Plexiform Layer; ONL: Outer
Nuclear Layer; RPE: Retinal Pigment Epithelium; Chor: Choroid.
doi:10.1371/journal.pone.0169865.g002
Nrp1 and Neovascularisation
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Alk1 and Alk5 mediated TGFB superfamily signalling [26]. In a pathological context, we have
previously demonstrated that inhibition of TGFB can reduce CNV lesion size in the laser-
induced CNV model [35–37]. This confirms that blocking of not only VEGF but also of other
targets can be effective in preventing CNV. Therefore, targeting Nrp1 as a treatment strategy
in ocular neovascular diseases might overcome anti-VEGF resistance.
In this report we used three different readout methods for the laser-induced CNV model:
in vivo OCT, and FA, and postmortem histology. Although, each of the three methods assess
slightly different aspects of CNV, all of them showed a clear effect caused by Nrp1 depletion.
Postmortem histological analysis has the advantage that vascular elements and invading
inflammatory cells can be identified separately and volume measurement of the CNV lesions
can be obtained with high precision using confocal microscopy [38]. However, dissection and
fixation artefacts might introduce noise into those volume measurements. In contrast, evaluat-
ing CNV lesions with OCT, measures the in vivo volume of CNV lesions and might be less
affected by histological processing artefacts. Many authors have assessed CNVs in vivo based
on FA images, but this approach does not take into account the height of the lesion and is
probably, out of the three methods discussed here, the least reliable to evaluate CNV area. On
the other hand, FA offers complementary data regarding vascular leakage, which the other two
methods cannot assess. In summary, an optimal assessment of CNV lesions is ideally based on
Fig 3. Laser-induced CNV assessed by fluorescein angiography and wholemount staining. In vivo FA images (A and B) and quantification of
fluorescein leakage areas (C) one week after CNV induction showed stronger leakage in wild type (A) compared to Nrp1ΔEC (B) mice (p<0.05; n = 5).
Postmortem lectin staining (D and E) and CNV area quantification (F) one week after CNV induction also showed more pronounced pathology in wild
type animals (p<0.05; n = 7). ONH indicates the optic nerve head.
doi:10.1371/journal.pone.0169865.g003
Nrp1 and Neovascularisation
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all three methods in conjunction, with OCT providing exact in vivo CNV volume measure-
ments, histology giving high resolution structural insight and FA allowing for a functional
readout of vessel permeability.
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